GlassScriptPhysician profile
Laura P Doty
NPI 1629274345
$1,086.52
in general payments reported to CMS, 2019-2025
13 companies · $39.44 in 2025
The $39.44 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $409 · 2022: $315 · 2023: $146 · 2024: $177 · 2025: $39.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $338 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $337.88 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $459.10 | 2021-2025 | Wegovy |
| Lilly USA, LLC | $196.64 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Rhythm Pharmaceuticals, INC. | $93.54 | 2021-2023 | Imcivree |
| Abbvie INC. | $59.76 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.37 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.02 | 2023-2024 | Xifaxan |
| Currax Pharmaceuticals LLC | $41.95 | 2021-2023 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $29.65 | 2021-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $28.06 | 2022 | |
| Pfizer INC. | $20.81 | 2025 | |
| Dexcom, INC. | $16.27 | 2021 | |
| Intra-Sana Laboratories | $14.30 | 2023 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Eisai INC. | $11.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Doty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.